{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:45:34Z","timestamp":1782719134951,"version":"3.54.5"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["NCC2510692-1"],"award-info":[{"award-number":["NCC2510692-1"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019R1A5A2027588"],"award-info":[{"award-number":["2019R1A5A2027588"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019M3E5D3073104"],"award-info":[{"award-number":["2019M3E5D3073104"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hereditary breast cancers (hBCs) exhibit genomic heterogeneity, but their underlying genomic instability and clinical implications remain unclear. We conducted whole-genome sequencing on 129\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    -negative hBCs, with subsets analyzed by methylome and transcriptome sequencing, and integrated COSMIC mutational, copy number (CN), and structural variation signatures. We identified four subtypes: homologous recombination-deficient (HRD), mutation-dominant (MUT), CN-dominant, and genome stable. HRD tumors exhibited genomic instability, including promoter hypermethylation and loss of heterozygosity at\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    . Some HRD-low hBC genomes showed elevated mutations and CN changes, indicating HRD-independent mechanisms. MUT tumors showed high tumor mutation burdens with APOBEC-associated kataegis and cytolytic\/immune-activation programs with M1 macrophage including upregulation of GZMA, GZMB, and large-scale transition. CN tumors were enriched for small-scale loss of heterozygosity maintaining euploidy with recurrent focal losses implicating classic tumor suppressors. Transcriptomics indicated immune and stromal infiltration in MUT and CN subtypes, respectively, suggesting subtype-specific therapeutic vulnerabilities. Functional analysis in cell lines suggests poly (ADP-ribose) polymerase inhibitors and cytotoxic chemotherapy sensitivity in HRD and CN tumors, whereas immune features in MUT tumors support vulnerability to immunotherapy. These findings suggest that distinct hBC subtypes delineated by genomic instability can advance insights into molecular heterogeneity beyond expression-based classifications and support an integrative genomic instability index (HRD score, ploidy, size-stratified CN burden, and signature exposures) for patient stratification and personalized therapeutic strategies.\n                  <\/jats:p>","DOI":"10.1038\/s12276-026-01693-4","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:28:43Z","timestamp":1776313723000},"page":"1254-1268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Delineation of the heterogeneity underlying genomic instability in hereditary breast cancers reveals four disease subtypes"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3628-1015","authenticated-orcid":false,"given":"Sunmin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seeyoun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejung","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong-Jo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhwa","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Chae","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7993-9701","authenticated-orcid":false,"given":"Tae-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0620-4058","authenticated-orcid":false,"given":"Sun-Young","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"1693_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1693_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer Statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1693_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2005.10.042","volume":"23","author":"JE Garber","year":"2005","unstructured":"Garber, J. E. & Offit, K. Hereditary cancer predisposition syndromes. J. Clin. Oncol. 23, 276\u2013292 (2005).","journal-title":"J. Clin. Oncol."},{"key":"1693_CR4","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1001\/jama.1985.03350370104033","volume":"253","author":"RW Sattin","year":"1985","unstructured":"Sattin, R. W. et al. Family history and the risk of breast cancer. JAMA 253, 1908\u20131913 (1985).","journal-title":"JAMA"},{"key":"1693_CR5","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","volume":"94","author":"D Thompson","year":"2002","unstructured":"Thompson, D., Easton, D. F. & Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J. Natl. Cancer Inst. 94, 1358\u20131365 (2002).","journal-title":"J. Natl. Cancer Inst."},{"key":"1693_CR6","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton, D. F. et al. Gene-panel sequencing and the prediction of breast-cancer risk. N. Engl. J. Med. 372, 2243\u20132257 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1693_CR7","doi-asserted-by":"publisher","first-page":"740227","DOI":"10.3389\/fonc.2021.740227","volume":"11","author":"L Shen","year":"2021","unstructured":"Shen, L., Zhang, S., Wang, K. & Wang, X. Familial breast cancer: disease related gene mutations and screening strategies for Chinese population. Front Oncol. 11, 740227 (2021).","journal-title":"Front Oncol."},{"key":"1693_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"1693_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1693_CR10","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli, M. L. et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin. Cancer Res. 22, 3764\u20133773 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1693_CR11","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274\u20131284 (2017).","journal-title":"Lancet Oncol."},{"key":"1693_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"1693_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.celrep.2012.12.008","volume":"3","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246\u2013259 (2013).","journal-title":"Cell Rep."},{"key":"1693_CR14","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.cell.2012.04.024","volume":"149","author":"S Nik-Zainal","year":"2012","unstructured":"Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979\u2013993 (2012).","journal-title":"Cell"},{"key":"1693_CR15","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/ng.3934","volume":"49","author":"P Polak","year":"2017","unstructured":"Polak, P. et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat. Genet 49, 1476\u20131486 (2017).","journal-title":"Nat. Genet"},{"key":"1693_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517\u2013525 (2017).","journal-title":"Nat. Med."},{"key":"1693_CR17","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160\u20131167 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1693_CR18","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch, A. et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22, 1736\u20131747 (2011).","journal-title":"Ann. Oncol."},{"key":"1693_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491\u2013498 (2011).","journal-title":"Nat. Genet."},{"key":"1693_CR20","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"1693_CR21","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"1693_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"1693_CR23","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s12276-022-00808-x","volume":"54","author":"SY Lee","year":"2022","unstructured":"Lee, S. Y., Wang, H., Cho, H. J., Xi, R. & Kim, T. M. The shaping of cancer genomes with the regional impact of mutation processes. Exp. Mol. Med. 54, 1049\u20131060 (2022).","journal-title":"Exp. Mol. Med."},{"key":"1693_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li, M. M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. 19, 4\u201323 (2017).","journal-title":"J. Mol. Diagn."},{"key":"1693_CR25","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1093\/nar\/gkg509","volume":"31","author":"PC Ng","year":"2003","unstructured":"Ng, P. C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812\u20133814 (2003).","journal-title":"Nucleic Acids Res."},{"key":"1693_CR26","first-page":"20","volume":"7","author":"I Adzhubei","year":"2013","unstructured":"Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. 7, 20 (2013).","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"1693_CR27","doi-asserted-by":"publisher","first-page":"15.19.1","DOI":"10.1002\/cpbi.17","volume":"56","author":"KM Raine","year":"2016","unstructured":"Raine, K. M. et al. ascatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data. Curr. Protoc. Bioinform 56, 15.19.1\u201315.19.17 (2016).","journal-title":"Curr. Protoc. Bioinform"},{"key":"1693_CR28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/bioinformatics\/btl646","volume":"23","author":"ES Venkatraman","year":"2007","unstructured":"Venkatraman, E. S. & Olshen, A. B. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23, 657\u2013663 (2007).","journal-title":"Bioinformatics"},{"key":"1693_CR29","doi-asserted-by":"crossref","unstructured":"Sztupinszki, Z. et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. npjBreast Cancer 4, 16 (2018).","DOI":"10.1038\/s41523-018-0066-6"},{"key":"1693_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","volume":"2","author":"NJ Birkbak","year":"2012","unstructured":"Birkbak, N. J. et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2, 366\u2013375 (2012).","journal-title":"Cancer Discov."},{"key":"1693_CR31","doi-asserted-by":"publisher","first-page":"20007","DOI":"10.1073\/pnas.0710052104","volume":"104","author":"R Beroukhim","year":"2007","unstructured":"Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. USA 104, 20007\u201320012 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1693_CR32","doi-asserted-by":"publisher","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","volume":"28","author":"T Rausch","year":"2012","unstructured":"Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333\u2013i339 (2012).","journal-title":"Bioinformatics"},{"key":"1693_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","volume":"52","author":"I Cortes-Ciriano","year":"2020","unstructured":"Cortes-Ciriano, I. et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat. Genet 52, 331\u2013341 (2020).","journal-title":"Nat. Genet"},{"key":"1693_CR34","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1093\/bioinformatics\/bty304","volume":"34","author":"V Geoffroy","year":"2018","unstructured":"Geoffroy, V. et al. AnnotSV: an integrated tool for structural variations annotation. Bioinformatics 34, 3572\u20133574 (2018).","journal-title":"Bioinformatics"},{"key":"1693_CR35","first-page":"None","volume":"2","author":"SMA Islam","year":"2022","unstructured":"Islam, S. M. A. et al. Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. Cell Genom. 2, None (2022).","journal-title":"Cell Genom."},{"key":"1693_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1693_CR37","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq \u2014 a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"1693_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"1693_CR39","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1693_CR40","first-page":"D498","volume":"48","author":"B Jassal","year":"2020","unstructured":"Jassal, B. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 48, D498\u2013D503 (2020).","journal-title":"Nucleic Acids Res."},{"key":"1693_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"1693_CR42","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1693_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 14, 7 (2013).","journal-title":"BMC Bioinform"},{"key":"1693_CR44","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1093\/bioinformatics\/btr167","volume":"27","author":"F Krueger","year":"2011","unstructured":"Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27, 1571\u20131572 (2011).","journal-title":"Bioinformatics"},{"key":"1693_CR45","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1093\/bioinformatics\/btu339","volume":"30","author":"Y Park","year":"2014","unstructured":"Park, Y., Figueroa, M. E., Rozek, L. S. & Sartor, M. A. MethylSig: a whole genome DNA methylation analysis pipeline. Bioinformatics 30, 2414\u20132422 (2014).","journal-title":"Bioinformatics"},{"key":"1693_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01655-y","volume":"25","author":"LVB Andersen","year":"2023","unstructured":"Andersen, L. V. B. et al. Non-BRCA1\/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness. Breast Cancer Res. 25, 69 (2023).","journal-title":"Breast Cancer Res."},{"key":"1693_CR47","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/annonc\/mdz132","volume":"30","author":"K Nones","year":"2019","unstructured":"Nones, K. et al. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. Ann. Oncol. 30, 1071\u20131079 (2019).","journal-title":"Ann. Oncol."},{"key":"1693_CR48","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00338","volume":"7","author":"S Yndestad","year":"2023","unstructured":"Yndestad, S. et al. Homologous recombination deficiency across subtypes of primary breast cancer. JCO Precis Oncol. 7, e2300338 (2023).","journal-title":"JCO Precis Oncol."},{"key":"1693_CR49","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 42, D980\u2013985 (2014).","journal-title":"Nucleic Acids Res"},{"key":"1693_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","journal-title":"Genome Biol."},{"key":"1693_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1126\/science.1253462","volume":"346","author":"EC de Bruin","year":"2014","unstructured":"de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251\u2013256 (2014).","journal-title":"Science"},{"key":"1693_CR52","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00534","volume":"2","author":"BJ Taylor","year":"2013","unstructured":"Taylor, B. J. et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. eLife 2, e00534 (2013).","journal-title":"eLife"},{"key":"1693_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"1693_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","volume":"144","author":"PJ Stephens","year":"2011","unstructured":"Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27\u201340 (2011).","journal-title":"Cell"},{"key":"1693_CR55","doi-asserted-by":"publisher","first-page":"a026070","DOI":"10.1101\/cshperspect.a026070","volume":"6","author":"AB Williams","year":"2016","unstructured":"Williams, A. B. & Schumacher, B. p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med. 6, a026070 (2016).","journal-title":"Cold Spring Harb Perspect Med."},{"key":"1693_CR56","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"1693_CR57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ctrv.2018.04.010","volume":"67","author":"M Papadimitriou","year":"2018","unstructured":"Papadimitriou, M., Mountzios, G. & Papadimitriou, C. A. The role of PARP inhibition in triple-negative breast cancer: unraveling the wide spectrum of synthetic lethality. Cancer Treat. Rev. 67, 34\u201344 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"1693_CR58","doi-asserted-by":"publisher","first-page":"975","DOI":"10.4143\/crt.2024.154","volume":"56","author":"YN Kim","year":"2024","unstructured":"Kim, Y. N., Gulhan, D. C., Jin, H., Glodzik, D. & Park, P. J. Recent advances in genomic approaches for the detection of homologous recombination deficiency. Cancer Res. Treat. 56, 975\u2013990 (2024).","journal-title":"Cancer Res. Treat."},{"key":"1693_CR59","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.2762","volume":"45","author":"G Ciriello","year":"2013","unstructured":"Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet 45, 1127\u20131133 (2013).","journal-title":"Nat. Genet"},{"key":"1693_CR60","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu, S. et al. Recent advances in targeted strategies for triple-negative breast cancer. J. Hematol. Oncol. 16, 100 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"1693_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.618332","volume":"12","author":"M Fabisik","year":"2021","unstructured":"Fabisik, M. et al. Regulation of inflammatory response by transmembrane adaptor protein LST1. Front. Immunol. 12, 618332 (2021).","journal-title":"Front. Immunol."},{"key":"1693_CR62","doi-asserted-by":"publisher","first-page":"560074","DOI":"10.3389\/fimmu.2020.560074","volume":"11","author":"MY Hachim","year":"2020","unstructured":"Hachim, M. Y., Hachim, I. Y., Talaat, I. M., Yakout, N. M. & Hamoudi, R. M1 polarization markers are upregulated in basal-like breast cancer molecular subtype and associated with favorable patient outcome. Front. Immunol. 11, 560074 (2020).","journal-title":"Front. Immunol."},{"key":"1693_CR63","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med 382, 810\u2013821 (2020).","journal-title":"N. Engl. J. Med"},{"key":"1693_CR64","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N. Engl. J. Med. 387, 217\u2013226 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1693_CR65","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi, S. et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat. Med. 31, 433\u2013441 (2025).","journal-title":"Nat. Med."},{"key":"1693_CR66","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso, F. et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)\/HER2(\u2212) breast cancer: a randomized phase 3 trial. Nat. Med 31, 442\u2013448 (2025).","journal-title":"Nat. Med"},{"key":"1693_CR67","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1158\/0008-5472.CAN-24-0169","volume":"84","author":"N Zhakula-Kostadinova","year":"2024","unstructured":"Zhakula-Kostadinova, N. & Taylor, A. M. Patterns of aneuploidy and signaling consequences in cancer. Cancer Res 84, 2575\u20132587 (2024).","journal-title":"Cancer Res"},{"key":"1693_CR68","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","volume":"606","author":"CD Steele","year":"2022","unstructured":"Steele, C. D. et al. Signatures of copy number alterations in human cancer. Nature 606, 984\u2013991 (2022).","journal-title":"Nature"},{"key":"1693_CR69","doi-asserted-by":"publisher","first-page":"8671","DOI":"10.1073\/pnas.0811835106","volume":"106","author":"C Swanton","year":"2009","unstructured":"Swanton, C. et al. Chromosomal instability determines taxane response. Proc. Natl. Acad. Sci. USA 106, 8671\u20138676 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1693_CR70","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41420-023-01306-3","volume":"9","author":"Z Guo","year":"2023","unstructured":"Guo, Z. et al. Cancer-associated fibroblasts induce growth and radioresistance of breast cancer cells through paracrine IL-6. Cell Death Discov. 9, 6 (2023).","journal-title":"Cell Death Discov."},{"key":"1693_CR71","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s41588-020-0678-2","volume":"52","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat. Genet. 52, 891\u2013897 (2020).","journal-title":"Nat. Genet."},{"key":"1693_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116426","volume":"44","author":"W Tang","year":"2025","unstructured":"Tang, W. et al. Integrated genomic and transcriptomic profiling of glioblastoma reveals ecDNA-driven heterogeneity and microenvironmental reprogramming. Cell Rep. 44, 116426 (2025).","journal-title":"Cell Rep."},{"key":"1693_CR73","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41586-024-08377-x","volume":"638","author":"KE Houlahan","year":"2025","unstructured":"Houlahan, K. E. et al. Complex rearrangements fuel ER(+) and HER2(+) breast tumours. Nature 638, 510\u2013518 (2025).","journal-title":"Nature"},{"key":"1693_CR74","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41586-022-04398-6","volume":"602","author":"EN Bergstrom","year":"2022","unstructured":"Bergstrom, E. N. et al. Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA. Nature 602, 510\u2013517 (2022).","journal-title":"Nature"},{"key":"1693_CR75","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10689-019-00144-6","volume":"18","author":"MK Ndugga-Kabuye","year":"2019","unstructured":"Ndugga-Kabuye, M. K. & Issaka, R. B. Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European. Fam. Cancer 18, 465\u2013469 (2019).","journal-title":"Fam. Cancer"},{"key":"1693_CR76","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.3390\/cancers15184522","volume":"15","author":"M Tapia","year":"2023","unstructured":"Tapia, M. et al. Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies. Cancers (Basel) 15, 4522 (2023).","journal-title":"Cancers (Basel)"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01693-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01693-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01693-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:02:37Z","timestamp":1782716557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01693-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":76,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1693"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01693-4","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}